home ver. 2.3. site index contact us

Message from the CEO
How We Work
Business Integrity
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

Management Biographies

ALEX KELLY R.Ph.
Group Vice President, Global Communications and Investor Relations
Schering-Plough Corporation
Kenilworth, New Jersey

Alex Kelly, R.Ph., is group vice president, Global Communications and Investor Relations, for Schering-Plough Corporation.

Kelly was named to his current position in October 2007 and is responsible on a global basis for Corporate External and Internal communications, Product Communications and Investor Relations. He is also responsible for communications related to the company's three core customer segments: Human Prescription Pharmaceuticals, Consumer Health Care and Animal Health. He joined Schering-Plough in April 2004 as vice president of Investor Relations.

Kelly has more than 18 years of experience in the pharmaceutical industry. Prior to joining Schering-Plough, Kelly was executive director of Investor Relations for Novartis Corporation. While at Novartis, he was based in Switzerland and focused on building relationships with European investors and analysts. Previously, Kelly was senior director of Investor Relations at Pharmacia Corporation. Prior to that assignment, he held a number of positions of increasing responsibility in Investor Relations and Sales at Pharmacia Corporation, Pharmacia & Upjohn and The Upjohn Company, where he began his career as a pharmaceutical sales representative.

Kelly holds a B.S. degree in pharmacy from Purdue University in Indiana.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough